ArticleCellular and molecular neurobiology2026
Changes in Purine Metabolism During Differentiation of Dopamine Neurons from Human Induced Pluripotent Stem Cells.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purines are a class of ubiquitous molecules required for fundamental processes in all cells. Purines are derived from two major sources: de novo synthesis, and salvage of preformed purine bases. The current studies provide evidence that the relative contributions of these two pathways change substantially as human induced pluripotent stem cells (iPSCs) differentiate into neurons. Expression of all genes in the de novo synthesis pathway decreases as pluripotent cells differentiate into neurons, but expression of the salvage pathway gene HPRT1 increases. This selective rise in HPRT1 gene expression corresponds with increased activity of its associated enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGprt). Similar changes in the expression of genes for the de novo pathway genes and for HPRT1 were found in a public database of gene expression for human brain development. The consequences of eliminating HGprt-mediated recycling were also evaluated in human-derived iPSCs with null HPRT1 mutations and stock iPSC lines that have been gene-edited to contain a null HPRT1 mutation. The absence of HGprt had no apparent impact on early neuronal differentiation, through 60 days of in vitro differentiation. Biochemical studies of purine content showed that that the absence of HGprt had little impact on intracellular purines, although large amounts of its substrate (hypoxanthine) accumulated in the tissue culture medium. Neurons derived from iPSCs without HGprt appeared morphologically and neurochemically indistinguishable from neurons derived from iPSCs where HGprt was intact. Interrogation of the transcriptome using RNA sequencing (RNAseq) indicated that the absence of HGprt had no consistent impact on gene expression during differentiation. Overall, these results suggest HGprt does not have a large impact on early neuronal differentiation and may instead play a more important role in later neuronal differentiation or function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.